
Please try another search
For the nine months ended 31 December 2021, Medicenna Therapeutics Corp revenues was not reported. Net loss increased 69% to C$19.4M. Higher net loss reflects Research and development - Balancing val increase of 86% to C$11M (expense), General and administration-balancing val increase of 42% to C$4.4M (expense), Salaries and benefits increase from C$985K to C$2.1M (expense).
Period Ending: | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -4.9 | -8.23 | -6.22 | -5.71 |
Net Income | -4.81 | -8.18 | -6.39 | -5.81 |
Period Ending: | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
---|---|---|---|---|
Total Assets | 26.11 | 30.09 | 37.34 | 42.25 |
Total Liabilities | 2.35 | 5.43 | 4.96 | 4.11 |
Total Equity | 23.76 | 24.66 | 32.38 | 38.15 |
Period Ending: | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -20.69 | -13.91 | -4.57 | -15.31 |
Cash From Investing Activities | 10.05 | 0.04 | 0.04 | 5.01 |
Cash From Financing Activities | 3.79 | 0.32 | 0.26 | 18.26 |
Net Change in Cash | -6.98 | -13.69 | -4.47 | 7.68 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review